Table 13 ISAR-TEST 4 trial
From: Evolutionary perspective of drug eluting stents: from thick polymer to polymer free approach
Characteristics | Time interval | First generation (Cypher)Â (%) | Second generation (Xience V)Â (%) | Third generation (Yukon PC)Â (%) |
|---|---|---|---|---|
MACE | 30 days | – | 4.5 | 4.4 |
ST | – | 0.4 | 0.4 | |
MACE | 12 months | – | 14.4 | 13.8 |
Cardiac death | – | 3.2 | 2.8 | |
TLR | – | 9.4 | 8.8 | |
ST | – | 1.5 | 1.0 | |
MACE | 2 years | – | 16 | 18.8 |
ST | – | 1.4 | 1.9 | |
TLR | – | 9.9 | 13.5 | |
MACE | 10Â years | 54.9 | 46 | 47.7 |
Cardiac death | 37.2 | 30.3 | 31.8 | |
MI | 9.1 | 7.9 | 7.7 | |
ST | 2.4 | 0.8 | 1.1 | |
TLR | 22.5 | 18.2 | 20.3 |